Adverum Biotechnologies (ADVM) Competitors $3.76 +0.81 (+27.46%) Closing price 04:00 PM EasternExtended Trading$3.78 +0.02 (+0.40%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. GALT, TVRD, NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, and NMRAShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Galectin Therapeutics (GALT), Tvardi Therapeutics (TVRD), Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Galectin Therapeutics Tvardi Therapeutics Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Galectin Therapeutics (NASDAQ:GALT) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability. Does the media prefer GALT or ADVM? In the previous week, Galectin Therapeutics had 3 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 5 mentions for Galectin Therapeutics and 2 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 1.14 beat Galectin Therapeutics' score of 0.41 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adverum Biotechnologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of GALT or ADVM? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, GALT or ADVM? Galectin Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Which has stronger earnings and valuation, GALT or ADVM? Galectin Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$47.05M-$0.64-7.50Adverum Biotechnologies$1M78.88-$130.93M-$7.85-0.48 Do analysts recommend GALT or ADVM? Galectin Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 25.00%. Adverum Biotechnologies has a consensus target price of $19.75, suggesting a potential upside of 425.27%. Given Adverum Biotechnologies' higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is GALT or ADVM more profitable? Galectin Therapeutics' return on equity of 0.00% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -225.32% Adverum Biotechnologies N/A -297.29%-101.40% SummaryAdverum Biotechnologies beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.90M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-0.4820.5276.4826.75Price / Sales78.88446.54531.95124.23Price / CashN/A46.0037.9261.55Price / Book1.119.6613.726.40Net Income-$130.93M-$53.02M$3.29B$271.62M7 Day Performance24.50%1.09%1.03%2.85%1 Month Performance32.39%7.93%6.32%9.64%1 Year Performance-49.87%10.48%81.16%31.62% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies3.8088 of 5 stars$3.76+27.5%$19.75+425.3%-57.8%$61.90M$1M-0.48190News CoveragePositive NewsHigh Trading VolumeGALTGalectin Therapeutics1.7593 of 5 stars$4.67+1.5%$6.00+28.5%+71.2%$294.68MN/A-7.309TVRDTvardi Therapeutics1.7668 of 5 stars$29.66-4.7%$64.25+116.6%N/A$291.73M$7.14M0.0080NGNENeurogene1.8735 of 5 stars$19.45-2.5%$46.17+137.4%-54.8%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical0.5515 of 5 stars$7.29-3.2%$8.00+9.7%+52.5%$281.68M$128.87M-5.56690MREOMereo BioPharma Group1.6251 of 5 stars$1.79+1.1%$7.40+313.4%-58.1%$281.43M$10M-25.5740ACBAurora Cannabis0.3839 of 5 stars$4.84-1.4%N/A-11.5%$277.19M$246.72M-25.471,130News CoverageRNACCartesian Therapeutics1.5996 of 5 stars$10.19-4.2%$40.00+292.5%-34.0%$276.66M$38.91M-0.1964News CoverageCADLCandel Therapeutics2.3644 of 5 stars$5.10+2.0%$20.00+292.2%-36.3%$274.48M$120K-7.3960MNPRMonopar Therapeutics2.5394 of 5 stars$41.48-6.2%$69.57+67.7%+1,581.5%$272.77MN/A-12.4610Analyst ForecastNMRANeumora Therapeutics2.567 of 5 stars$1.66-1.2%$7.14+330.3%-87.1%$272.07MN/A-1.06108Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies GALT Alternatives TVRD Alternatives NGNE Alternatives LFCR Alternatives MREO Alternatives ACB Alternatives RNAC Alternatives CADL Alternatives MNPR Alternatives NMRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts